The healthcare sector might not be at the forefront of exciting developments like artificial intelligence, but because good ...

This is a huge setback for the company, leaving SYRS without a pipeline candidate. In the same press release ... evaluated the triple therapy of tamibarotene in combination with AbbVie’s ABBV ...

“The drug discovery process is long, inefficient and costly, with the majority of new drugs failing during clinical trials,” ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy ...

In addition to his positions at Prometheus and Abbvie, Mr. Stenhouse held an executive leadership ... as we head toward commercialization of obefazimod and strengthen our pipeline.” Mark Stenhouse, ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

Key Takeaways from the Multiple Sclerosis Pipeline Report DelveInsight's multiple sclerosis ... Oryzon Genomics, GeNeuro SA, AbbVie, BrainStorm Cell Therapeutics, NeuroSense Therapeutics, Denali ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & ...

The Series D financing will support the clinical development of two ADCs.

Now, it seems a key part of that effort will come from its cardiovascular disease pipeline. During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy ...